Cetrorelix vs Ganirelix
How they differ
- FDA status, the same for both (FDA-approved). Cetrorelix: FDA-approved as Cetrotide for use in controlled ovarian stimulation.1,2 Ganirelix: FDA-approved as ganirelix acetate for use in controlled ovarian hyperstimulation.3,4
- Kinds of studies cited. Cetrorelix: smaller controlled human trials. Ganirelix: large randomized human trials. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Cetrorelix | Ganirelix |
|---|---|---|
| What it is | A synthetic analogue of GnRH with amino acids changed at five positions, which blocks rather than activates the GnRH receptor, according to the label.1 | A synthetic decapeptide derived from natural GnRH with amino acids changed at six positions, giving it strong GnRH-blocking activity, according to the label.3 |
| FDA status | FDA-approved FDA-approved as Cetrotide for use in controlled ovarian stimulation1,2 FDA-approved. Drugs@FDA lists Cetrotide with an original approval date of August 11, 2000. The cited label has no boxed warning.1,2 | FDA-approved FDA-approved as ganirelix acetate for use in controlled ovarian hyperstimulation3,4 FDA-approved. Drugs@FDA lists Organon’s ganirelix acetate, NDA 021057, with an original approval date of July 29, 1999. The cited label has no boxed warning.3,4 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.5 | Not among the six peptides the policy lists.5 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited | Smaller controlled human trials
|
|
| Records collected | 26 ClinicalTrials.gov records and 22 PubMed records collected | 27 ClinicalTrials.gov records and 6 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1CETROTIDE (cetrorelix acetate) kit · SPL version 18 · published 2025-09-29 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 2Drugs@FDA: CETROTIDE (cetrorelix acetate), NDA 021197 · original approval August 11, 2000 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3Ganirelix acetate injection, solution (Organon LLC) · SPL version 10 · published 2026-10-12 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 4Drugs@FDA: Ganirelix acetate (Organon), NDA 021057 · original approval July 29, 1999 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 5HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026